These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The cost of asthma treatment in Spain and rationalizing the expense. Nieto A; Alvarez-Cuesta E; Boquete M; Mazón A; de la Torre F J Investig Allergol Clin Immunol; 2001; 11(3):139-48. PubMed ID: 11831444 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of asthma therapy: a comprehensive review. Domínguez-Ortega J; Phillips-Anglés E; Barranco P; Quirce S J Asthma; 2015; 52(6):529-37. PubMed ID: 25539023 [TBL] [Abstract][Full Text] [Related]
10. [Economic cost of treating the patient with asthma in Spain: the AsmaCost study]. Martínez-Moragón E; Serra-Batllés J; De Diego A; Palop M; Casan P; Rubio-Terrés C; Pellicer C; Arch Bronconeumol; 2009 Oct; 45(10):481-6. PubMed ID: 19525051 [TBL] [Abstract][Full Text] [Related]
11. The Cost of Asthma Treatment in Phramongkutlao Hospital: Population-Based Study in Adults. Boonpiyathad T; Yimsawad S; Sangasapaviriya A J Med Assoc Thai; 2016 Jan; 99(1):51-7. PubMed ID: 27455824 [TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain. Vennera Mdel C; Valero A; Uría E; Forné C; Picado C Clin Drug Investig; 2016 Jul; 36(7):567-78. PubMed ID: 27142072 [TBL] [Abstract][Full Text] [Related]
13. Use of Biological Agents in Asthma: Pharmacoeconomic Lessons Learned From Omalizumab. Draikiwicz S; Oppenheimer J Chest; 2017 Feb; 151(2):249-251. PubMed ID: 28183482 [No Abstract] [Full Text] [Related]
15. The relationship between pharmaceutical costs, disease severity, and health-related quality of life in asthmatics in Swedish primary care. Arnlind MH; Nokela M; Rehnberg C; Jonsson EW J Asthma; 2006 Oct; 43(8):585-91. PubMed ID: 17050222 [TBL] [Abstract][Full Text] [Related]
16. Factors affecting UK primary-care costs of managing patients with asthma over 5 years. Dasgupta R; Guest JF Pharmacoeconomics; 2003; 21(5):357-69. PubMed ID: 12627989 [TBL] [Abstract][Full Text] [Related]
17. [Costs of allergy therapy]. Horak F Wien Med Wochenschr; 1999; 149(14-15):444-6. PubMed ID: 10584291 [No Abstract] [Full Text] [Related]
18. The impact of disease management on outcomes and cost of care: a study of low-income asthma patients. Rossiter LF; Whitehurst-Cook MY; Small RE; Shasky C; Bovbjerg VE; Penberthy L; Okasha A; Green J; Ibrahim IA; Yang S; Lee K Inquiry; 2000; 37(2):188-202. PubMed ID: 10985112 [TBL] [Abstract][Full Text] [Related]
19. Allergic Rhinitis and its Impact on Asthma update (ARIA 2008). The perspective from Spain. Mullol J; Valero A; Alobid I; Bartra J; Navarro AM; Chivato T; Khaltaev N; Bousquet J J Investig Allergol Clin Immunol; 2008; 18(5):327-34. PubMed ID: 18973095 [TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics of asthma treatment. Cleland J; Thomas M; Price D Expert Opin Pharmacother; 2003 Mar; 4(3):311-8. PubMed ID: 12614183 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]